VanEck Biotech ETF (BBH)
| Assets | $423.66M |
| Expense Ratio | 0.35% |
| PE Ratio | 15.67 |
| Shares Out | 2.70M |
| Dividend (ttm) | $0.71 |
| Dividend Yield | 0.46% |
| Ex-Dividend Date | Dec 18, 2023 |
| Payout Ratio | 7.22% |
| 1-Year Return | -4.23% |
| Volume | 53,720 |
| Open | 156.77 |
| Previous Close | 157.33 |
| Day's Range | 153.47 - 157.33 |
| 52-Week Low | 142.51 |
| 52-Week High | 171.05 |
| Beta | 0.82 |
| Holdings | 27 |
| Inception Date | Dec 20, 2011 |
About BBH
Fund Home PageThe VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.
Top 10 Holdings
68.13% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 15.02% |
| Vertex Pharmaceuticals Incorporated | VRTX | 9.52% |
| Gilead Sciences, Inc. | GILD | 7.80% |
| Regeneron Pharmaceuticals, Inc. | REGN | 7.70% |
| Moderna, Inc. | MRNA | 5.78% |
| IQVIA Holdings Inc. | IQV | 4.96% |
| argenx SE | ARGX | 4.44% |
| Biogen Inc. | BIIB | 4.36% |
| ICON PLC | ICLR | 4.33% |
| Illumina, Inc. | ILMN | 4.22% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 18, 2023 | $0.7127 | Dec 22, 2023 |
| Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
News
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
A Divergence Has Occurred In Healthcare
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.